Inovio Pharmaceuticals Inc. (INO)
INO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/0001055726-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001055726 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $65K |
| Net income | -$84.9M |
| Operating income | -$86.8M |
| Net margin | -130000.0% |
| Operating margin | -132871.3% |
| Revenue growth | -70.0% |
| Cash | $44.3M |
| Total assets | $74.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4013.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2027." | 10-Q 2026-11-10 |
| Cash and burn | $47.0M cash; operating cash flow -$18.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 187,306,884 (2026-11-10); 53,571,675 a year earlier; 272,986,424 three years earlier. 3y figure adjusted for splits (1-for-12 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2024-01-25 | Source 2024-01-25 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 7 424B5 takedowns, 6 at the market | Latest 2026-11-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $299K | -$49.2M | -$15.3M | $47.0M | No debt tags | $299K | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $0 | -$6.0M | -$18.0M | $31.5M | No debt tags | $0 | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $0 | -$19.7M | -$21.6M | $26.3M | No debt tags | $0 | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $0 | $3.8M | -$19.4M | $44.3M | No debt tags | $65K | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $0 | -$45.5M | -$21.6M | $36.6M | No debt tags | $182K | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $0 | -$23.5M | -$20.8M | $24.4M | No debt tags | $182K | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $65K | -$19.7M | -$26.9M | $39.9M | No debt tags | $283K | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $117K | -$19.4M | -$19.7M | $65.8M | $0 | $218K | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +17.2% |
| 1 month | +43.0% |
| 3 months | +58.9% |
| Year to date | -17.8% |
| 1 year | -26.7% |
| From 52-week high | -45.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TTRX | Turn Therapeutics Inc. | $8.55 | -8.51% | $261.4M |
| PRLD | Prelude Therapeutics Incorporated | $3.41 | -1.16% | $272.1M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier